The Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) clinical trial—a prospective study designed to reduce gaps in cancer treatment completion and survival among Black and white patient populations— found that identifying and addressing obstacles that kept patients from finishing radiation treatments improved five-year survival rates for all patients and erased the survival gap between Black and white patients.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
